CHIRON Biotech

What CHIRON Biotech does

CHIRON Biotech is an international R&D consortium developing a multimaterial 3D bio-inkjet platform for the biomedical sector, with the project coordinated by Concr3de B.V. from Rotterdam, Netherlands. The consortium brings together two SMEs (Concr3de and IPC - Innovative Polymer Compounds) and three academic research centers (University Medical Center Utrecht, Trinity College Dublin, and Eindhoven University of Technology), and is funded by the Eurostars programme. Its technology stack combines the Armadillo Bio industrial bioprinter and Chameleon desktop bioprinter (each with 1024 nozzles per printhead and multimaterial inkjet capability), the Noah software suite for experiment management, and a proprietary biomaterials portfolio (BIOPOL bioinks, OsteoPol composite biopolymers/bioceramics, and OsteoCer bioresorbable implants).

The platform targets tissue engineering, regenerative medicine, personalized medicine, drug discovery, and bioprocessing applications, addressing limitations in creating complex biomimetic tissue environments at industrial throughput. Disclosed customers include Eindhoven University of Technology, Trinity College Dublin, and the University of Milano Bicocca, all academic research institutions. The company makes money through hardware sales of bioprinters, recurring consumables (bioinks, biopowders, biomaterials), and R&D co-development services, with quote-based pricing and direct enterprise engagement via its website rather than transactional channels.

The operating model is unusual for a commercial-stage biotech: the entity is structured as a grant-funded consortium rather than a traditional venture-backed startup, with no disclosed equity funding, no disclosed revenue figures, and a headcount of 1-10. Ownership is founder-led through Concr3de's Matteo Baldassari, with academic partners contributing research expertise rather than equity. Certification profile is anchored by partner IPC's ISO 13485 accreditation for medical-grade polymer compounding, which is a prerequisite for downstream medical device applications.

Name

CHIRON Biotech

Legal name

Concr3de B.V.

Website

https://chiron-biotech.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

CHIRON Biotech is an international R&D consortium developing a multimaterial 3D bio-inkjet platform combining bioprinters, bioinks, and software for biomedical research institutions, pharmaceutical companies, and medical device developers working in tissue engineering, regenerative medicine, and drug discovery.

Ownership category

akta.pro rank

Product category

3D Bioprinting Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Plastics Material and Resin Manufacturing (325211)

SIC

Services-Commercial Physical & Biological Research (8731), Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820)

akta.pro primary industry

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

akta.pro secondary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

Keywords

• Bioprinting platforms
• Biomedical research equipment
• Biofabrication technology
• Bioink materials
• Regenerative medicine tools

Headquarters

HQ city

Rotterdam

HQ country

Netherlands

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Bioprinter Hardware Sales: Sale of multimaterial inkjet bioprinters (Armadillo Bio and Chameleon platforms) to research institutions and biomedical companies. Customizable systems with add-ons for specific research requirements.
2. Biomaterials and Consumables: Sales of bioinks (BIOPOL), biopowders, and bioceramic materials (OsteoPol, OsteoCer) for use with bioprinting platforms.
3. R&D Services and Support: Collaborative development and support services for companies and research institutes developing innovative solutions for the biomedical industry.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CHIRON Biotech develops a multimaterial bioprinting platform that combines hardware (industrial and desktop inkjet bioprinters), proprietary biomaterials (bioinks, biopowders, bioceramic beads), and software (Noah) to enable biomedical research and production. The offering targets tissue engineering, regenerative medicine, drug discovery, bioprocessing, and personalized medicine applications for research institutions and biomedical companies. The project is coordinated by Concr3de B.V. and developed as an international R&D consortium with two SMEs and two academic research centers.

Product overview

CHIRON Biotech offers a multimaterial bioprinting platform comprising hardware, software, and biomaterials. The core product is a customizable Multimaterial 3D bio-inkjet platform for biomedical applications, regenerative medicine, and drug discovery. Hardware products include Armadillo Bio (high throughput industrial platform with 38x30x30 cm printing volume) and Chameleon (compact desktop bioprinter for research institutes). Noah Software Suite provides experiment management across all printers. The biomaterial portfolio includes BIOPOL ink (bioinks with nanoparticle dispersion), OsteoPol beads and scaffolds (composite biopolymers/bioceramics), and OsteoCer Implants (bioresorbable implants). R&D services support co-development with partners. The consortium partners include Concr3de, IPC - Innovative Polymer Compounds, Trinity College Dublin, UMC Utrecht, and Eindhoven University of Technology.

Differentiator

Problem solved

Functional benefit

Brands

• ArmadilloBio: Innovative multimaterial inkjet platform for high throughput and industrial applications in bioprinting
• Chameleon
• Noah
• BIOPOL ink
• OsteoPol beads
• OsteoCer Implants

Products and services

• Armadillo Bio Bioprinter High throughput industrial multimaterial inkjet bioprinter with 1024 nozzles per printhead, 1-3 printheads, UV and near-infrared curing systems, and 38x30x30 cm printing volume for industrial biomedical applications.
• Chameleon Desktop Bioprinter

Quantifiable outcome

• Resolution of 0.06 mm with adjustable layer size from 10 to 300 microns
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• IPC - Innovative Polymer CompoundscoreStrategic or Co-development Partner · 1 July 2021ISO 13485 approved compounder of medical grade engineering polymers. Joint venture providing compounding capabilities and expanding the biomaterials portfolio. Exports to 23 countries.
• Concr3de B.V.coreStrategic or Co-development PartnerSME and main project partner, specialized in additive manufacturing systems and materials. Founder Matteo Baldassari leads and coordinates the CHIRON consortium. Provides hardware development and bioprinter manufacturing capabilities.
• University Medical Center Utrecht (UMC Utrecht)coreStrategic or Co-development PartnerResearch institute with expertise in biofabrication and tissue engineering. Led by Prof. Jos Malda, head of the Utrecht Biofabrication Facility. Focuses on biomaterials development and bioprocesses.
• Trinity College DublincoreStrategic or Co-development PartnerResearch institute led by Prof. Daniel Kelly, focusing on musculoskeletal tissue engineering and 3D bioprinting. Over 180 publications and €18 million in research funding.
• Eindhoven University of Technology (TU/e)coreStrategic or Co-development PartnerResearch institute partner providing expertise in biomedical engineering and biofabrication. Home to researchers like Dr. Miguel Castilho and Dr. María Paula Vena.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BICO (formerly Cellink): Largest dedicated bioprinting and bioconvergence company, offering bioprinters, bioinks and lab automation solutions that directly overlap CHIRON's hardware + bioink + applications stack for tissue engineering, regenerative medicine and drug discovery.
• Organovo Holdings: Pioneer in 3D bioprinting of human tissues for research and therapeutic applications, targeting similar use cases in tissue engineering and drug discovery with comparable multimaterial biofabrication ambitions.
• Aspect Biosystems: Developer of microfluidic 3D bioprinting technology and bioprinted tissue products for drug discovery and regenerative medicine; directly comparable as a platform bioprinting company spanning hardware, biomaterials and applications.
• RegenHU: Swiss bioprinter manufacturer offering multi-head, multimaterial bioprinters and bioinks for tissue engineering and regenerative medicine — a direct technology competitor in the multimaterial bio-inkjet space CHIRON targets.

Emerging players

• Poietis: French bioprinting company using laser-assisted bioprinting for tissue engineering and regenerative medicine; overlaps CHIRON's biofabrication R&D focus and target customer segments.
• Regemat 3D: Spanish bioprinter vendor offering extrusion-based bioprinters and biomaterials for research and clinical applications; comparable as a focused bioprinting hardware + biomaterials vendor serving research institutes.
• TissueLabs: Brazil-based bioprinting company commercialising bioprinters, bioinks and services for tissue engineering and regenerative medicine; comparable scale and full-stack offering to CHIRON.

Broad incumbents

• 3D Systems: Diversified 3D printing incumbent with bioprinting and regenerative-medicine programmes (formerly through partners and acquisitions); competes in the broader '3D printing meets healthcare' space and could absorb CHIRON's market.
• Stratasys: Global 3D printing leader with PolyJet multimaterial printing technology relevant to CHIRON's multimaterial approach; incumbent that smaller bioprinters must differentiate against.
• Materialise: Large-scale 3D printing services and software provider with established medical-device and personalised-medicine workflows; broad incumbent that competes for the same biomedical customers as CHIRON's platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chiron-biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CHIRON Biotech